Cancer is known to be one of the leading causes of deaths worldwide. In fact, as per the WHO, close to 10 million cancer related deaths were reported in 2020. Further, it is estimated that, by the end of 2040, 27.5 million new cancer cases will be added to the global numbers, exerting tremendous physical, emotional and financial strain on affected individuals, their families, communities and national health systems. Although there are several treatment options available to control disease progression and keep malignant cells from spreading throughout the body, lasting remission is difficult to achieve. In this context, immunotherapies, a relatively recent addition to the gamut of anticancer interventions, have demonstrated significant promise. Amidst the current initiatives undertaken to develop more targeted anti-cancer therapies, T-cell immunotherapies (specifically CAR-T therapies, TCR therapies and TIL therapies) have emerged as a promising option, owing to their ability to eradicate tumor cells from the body with minimal treatment-related side effects.
T-Cell Immunotherapies – Current Market Landscape
Presently, more than 250 companies are engaged in the development of more than 1,200 early and late-stage T-cell therapies, worldwide. Several promising leads are anticipated to be commercially launched over the coming decade, following which the market is projected to grow at a substantial pace.
T-Cell Therapies – Partnerships and Collaborations
A rise in partnerships, in the recent past, involving both international and indigenous stakeholders, validate the growing interest in this domain; maximum number of such deals were signed in 2021.
T-Cell Immunotherapies – Funding and Investments
Several investors, having realized the opportunity within this upcoming segment of cancer immunotherapy, have invested USD 30 billion, across 335+ instances, during the period 2000-2022.
T-Cell Therapies – Patent Analysis
The R&D activity related to T-cell immunotherapies is largely concentrated on development of CAR-T cell therapies, considering the fact that 96% of the total number of patents were filed for CAR-T cell therapies. In addition, most of the patents in this domain are patent applications (84%), followed by granted patents (13%).
T-Cell Immunotherapies – Market Forecast and Opportunity Analysis
In the long-term, the overall projected opportunity is likely to be well distributed across key market segments, including type of therapy, indications, target antigen, key players and geographical regions; the market is expected to grow at a CAGR of ~23% by 2035.
Over the past few years, T-cell immunotherapy has been successful in carving out a significant niche in the pharmaceutical market. A number of such targeted therapies have already been approved whilst a robust development pipeline indicates that the T-cell immunotherapy market is likely to grow at a steady pace in the foreseen future. Moreover, the ongoing research activity in this field has led to the discovery of several novel molecular targets, further strengthening the research pipelines of companies engaged in this market.
Currently, several industry and non-industry players are focused on the development of technologies that are capable of overcoming the existing roadblocks in the production / adoption of T-cell therapies. Driven by the availability of innovative technology platforms, lucrative funding and encouraging clinical trial results, the T-cell immunotherapies market is poised to grow in the long-run, as multiple product candidates are expected to receive marketing approval in the coming decade. You can also download the SAMPLE REPORT on this topic by Roots Analysis by clicking on the link here…https://www.rootsanalysis.com/reports/view_document/t-cell-therapies-market/261.html